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PREFACE 
 
 
 
In the context of the multi-complexity and intense research process that modern medicine is 
characterized by, the properly designed clinical trial protocols could enhance the role of the 
investigator and contribute in the production of reliable research outcomes as well as to the rational 
use of resources allocated to medical research. 
Worldwide, a high number of people of various age groups are affected from sudden 
idiopathic sensorineural hearing loss. After the onset of such a disease, a negative impact on 
communication, relationships, and generally the quality of life of patients and their environment 
is hard to be avoided. There are several types of hearing loss due to a various etiology. Based on 
relevant literature, as well as on clinical practice, corticosteroids are considered as the best 
treatment by many authors; however, there is no gold standard for treating this disease because of 
its wide etiology.  Furthermore, corticosteroids cannot be administered to patients with specific 
health problems and may cause specific side effects. These facts lead to the need for a treatment 
with less limitations and side effects in the global scientific research. 
In the frame of this thesis, a protocol for a randomized clinical trial is specially designed 
which could be useful in investigating the effect of magnesium in patients with sudden idiopathic 
sensorineural hearing loss. 
The thesis was elaborated in the Laboratory of Biomathematics, of the University of 
Thessaly School of Medicine. It is structured in 10 chapters including all the ideas, criteria and 
rules related to the rational design and development of a randomized clinical trial protocol. 
I am indebted to express my gratitude to my supervisor Professor Ioannis Stefanidis for his 
useful comments, remarks and engagement through the learning process of this master thesis. 
Furthermore, I would like to thank Professor Elias Zintzaras and Professor Georgios Hadjigeorgiou 
for introducing me to the topic as well as for their support and valuable comments.  
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  CHAPTER 1  
INTRODUCTION 
 
 
 
 
1.1  Background and Rationale for the study  
Worldwide, hearing loss affects millions of people and can potentially have a negative 
impact on communication, relationships, and generally the quality of life of patients and their 
environment (World Health Organization, 2009). There are several types of hearing loss due to a 
various etiology. This study includes subjects with Sudden Idiopathic Sensorineural Hearing Loss 
(SSNHL), which pathophysiology usually deal with viral or vascular etiology. 
The most common approach to treatment of SSNHL is with steroids and mostly 
corticosteroids, which has been deemed by many authors to be the gold standard of treatment 
(Chandrasekhar, 2003). 
Adding oral magnesium to the traditional steroid treatment of idiopathic SSNHL may 
enhance the improvement in hearing. This noninvasive treatment seems to be relatively safe and 
free of side effects (Nageris et al., 2004). 
This trial is designed to study the effectiveness of oral magnesium in combination with oral 
corticosteroid treatment in patients with unilateral idiopathic SSNHL. Necessary examinations 
will be performed in order to exclude any other etiology resulting to hearing loss according to 
exclusion criteria of this protocol. 
 
1.2  Sudden Sensorineural Hearing Loss 
The US National Institute for Deafness and Communication Disorders (NIDCD) defines 
SSNHL as the idiopathic loss of hearing of at least 30 dB over at least 3 contiguous test frequencies 
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occurring within 72 hours or less (National Institute of Health (2000). The incidence of SSNHL is 
considered to be 5 to 20 per 100,000 patients per year (Alexander and Harris, 2013). The reported 
incidence is lowest in patients aged 20 to 30 years (4.7 per 100,000) and highest in those aged 50 
to 60 years (15.8 per 100,000) (Byl, 1984). A spontaneous recovery not followed by treatment has 
been reported to range from 30-60% (Fitzgerald and McGuire, 2007).  The fact that several patients 
experience a spontaneous resolution of their deafness without having seeked treatment, makes the 
actual incidence higher (Byl, 1977). Sudden hearing loss affects the two sexes equally. 
Approximately 90% of cases occur unilaterally (Ogasawara et al., 1993). The etiology of SSNHL 
can be classified into specific categories with multiple conditions within each of these categories, 
associated with sudden hearing loss:  
(1) viral and infectious (meningococcal meningitis, herpes viruses (simplex, varicella zoster), 
cytomegalovirus, mumps, HIV, mycoplasma, toxoplasmosis, syphilis, measles (rubeola), 
rubella, Lyme disease.),  
(2) autoimmune (lupus erythematosus, polyarteritis nodosa, Cogan’s syndrome, Wegener 
granulomatosis, relapsing polychondritis, Behçet syndrome, Kawasaki disease, temporal 
arteritis (Horton disease).),  
(3) traumatic (perilymphatic fistula, temporal bone fracture, barotrauma, blast injury, etc),  
(4) vascular (vertebrobasilar vascular attack, stroke, sickle cell disease, decompression, 
sickness from SCUBA diving),  
(5) neurological (multiple sclerosis, migraine),  
(6) tumoral (vestibular schwannoma (acoustic neuroma), leukemia, myeloma, metastasis to 
internal auditory canal, meningeal carcinomatosis),  
(7) Ototoxic (amikacin, vancomycin, erythromycin, cisplatin) 
(8) pressure related (hydrops, Ménière’s disease).Sudden hearing loss 
 
 
1.3  Corticosteroids 
           Oral corticosteroid therapy is the treatment generally accepted and proved to be effective 
in selected studies and most importantly when compared to placebo in several randomized 
controlled trials and meta-analyses (Moskowitz et al., 1984; Wilson et al., 1980). Systemic steroids 
have been labeled the gold standard for treatment of SSNHL, but such a conclusion was based on 
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a comparison of systemic steroids with placebo (Chandrasekhar, 2003). A burst of steroids such 
as prednisone is usually administered as a treatment of SSNHL. Regarding the management and 
steroids for SSNHL, there is a great variability in otology/neurotology practice (Coelho et al., 
2011). There has been research on administering preferred oral steroids alone, a combination of 
oral and intratympanic steroids and also intravenous steroids (Eisenman and Arts, 2000). Evidence 
to date for a good effect is generally mixed. Two meta-analysis studies of steroid treatment (Conlin 
and Parnes, 2007; Labus et al., 2010) suggested there was no benefit. In a more recent evidence 
based review, Lawrence and Thevasagayam (2015) suggested that either oral or intratympanic 
steroids should generally be offered. Even more recently, Gao and Liu (2016), in another meta-
analysis, suggested that combined intratympanic and systemic steroids provide better outcomes 
than systemic steroids alone (Hain, 2016). On the basis of the study of Wilson et al, oral 
corticosteroids in moderate doses are the most widely accepted treatment option for idiopathic 
SSNHL in patients with intermediate audiograms (i.e., neither limited to middle frequency loss 
nor with profound loss at all frequencies) and this protocol is going to be based on oral 
corticosteroid treatment (Wilson et al., 1980). 
 
1.4  Magnesium Aspartate 
Magnesium is involved in the regulation of cell membrane permeability, neuromuscular 
excitation, and energy consumption and production (Guenther et al., 1989). A metabolic cellular 
cascade of events is involved in the putative magnesium mechanism within the auditory system.  
Specifically, within the inner ear, magnesium regulates the membrane permeability of the 
calcium channel in the hair cells, having as a deficiency consequence the over-influx of calcium 
and sodium, a decrease in potassium by passive diffusion an increased release of glutamate via 
exocytosis, and overstimulation of N-methyl-D-aspartate receptors on the auditory nerve fibers 
(Attias et al., 1994). This diminishes the electrochemical gradient required for sensory transduction 
and attempting to restore this gradient, the hair cells expend energy, which can ultimately lead to 
cell death (Attias et al., 1994). 
This lack of appropriate magnesium intake may have negative consequences in hearing. 
An extracellular magnesium deficiency may also lead to the release of hormones that decrease 
muscle tone, catecholamine and prostaglandin secretion, thereby with subsequent vasoconstriction 
and a reduction of blood flow to the cochlea (Thorne and Nuttall, 1987; Günther et al., 1978)  
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Metabolic stress within the inner ear, such as a possible noise exposure also places high 
demands on cell energy stores (Spoendlin, 1962). The exact mechanism by which magnesium 
supplementation works remains unclear. However, it is speculated that supplementation increases 
magnesium levels within the inner ear to maintain normal membrane characteristics and cell 
energy demands. Increased magnesium levels are also thought to improve the microcirculation of 
the inner ear, therefore, improving blood flow to the cochlea (Altura et al., 1992)   
Recent studies of both noise-induced hearing loss and idiopathic sensorineural hearing loss 
have suggested that magnesium supplementation may even lessen the severity of tinnitus in 
patients. Magnesium improved hearing recovery and lessened tinnitus in patients with idiopathic 
sudden hearing loss (Gordin et al., 2002). More recently, Nageris et al. (2004) showed in a 
controlled study that magnesium was a relatively safe and convenient adjunct to corticosteroid 
treatment for enhancing the improvements of hearing in acute-onset sensorineural hearing loss. 
The protective effect of magnesium in noise-induced hearing loss has been previously reported 
whereas the therapeutic is still on research (Ising et al., 1982; Scheibe et al., 2000). 
 
1.5  Rationale for Dose Selection 
The Recommended Daily Allowance (RDA) for magnesium in adults is 4.5 mg/kg (Saris 
et al., 2000); however, according to studies on Americans, we usually fall short of the RDA for 
magnesium by 100 mg daily (Standing Committee on the Scientific Evaluation of Dietary 
Reference Intakes, 1997). 
Taking into consideration results of the trials of Nageris et al. (2004) and Slattery et al. 
(2005) treatment studies, that showed that a 14-day course of oral prednisone 60 mg per day to be 
approximately comparable for efficacy and safety, following a taper therapy treatment for one 
more week aiming to a gradual decrease of two daily doses of 20 mg of prednisone for 3 days and 
one daily dose of prednisone for 4 days. Retrospective reviews found patients who were treated 
within two weeks of symptoms with at least 60 mg prednisone daily did better than patients who 
received lower doses of glucocorticoid, or who were treated later in their course (Slattery et al., 
2005). 
In our study protocol, the magnesium aspartate dose was selected to be 167mg in 200ml of 
lemonade per mouth once daily.  
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As placebo, sodium aspartate 167mg in 200ml of lemonade will be administered for oral 
intake once daily (Nageris et al., 2004; Slattery et al., 2005). 
 
1.6  Preclinical Safety Data 
Corticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in 
blood pressure. These mineralocorticoid effects are most significant with fludrocortisone, followed 
by hydrocortisone and cortisone and finally by prednisone and prednisolone. The remaining 
corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have 
minor reported mineralocorticoid activities. However, large doses of any corticosteroid can 
demonstrate these effects, particularly if given for longer than brief periods. Therapy with 
corticosteroids should be administered cautiously in patients with preexisting fluid retention, 
hypertension, congestive heart failure, and/or renal dysfunction. Dietary sodium restriction and 
potassium supplementation may be advisable (Klepikov et al., 1988). 
Mg2+ has several vital functions in the human body. The main body source of Mg2+ is the 
skeletal system (70%), whereas the serum contains only 0.3%. The main regulator of the Mg2+ 
levels is the kidney, which secretes it whenever there is an excess and reabsorbs when there is a 
deficiency. Hormones such as calcitonin, aldosterone, thyroxin, and insulin influence Mg2+ 
balance. Magnesium is likely safe for most people when taken by mouth appropriately or when 
the prescription-only, injectable product is used correctly. In some people, magnesium might cause 
stomach upset, nausea, vomiting, diarrhea, and other side effects, such as mild hypotension. Doses 
less than 350 mg daily are safe for most adults (Schanne et al., 1979). 
 
1.7  Clinical Safety Data  
Positive findings were noted in guinea pigs that were given magnesium injections 
immediately after use of the transient threshold shift strategy (Scheibe et al., 2000). 
It has been recently demonstrated in Randomized Clinical Trials (RCTs) results that a 
preventive Mg2+ supplement can reduce ischemia-induced hearing loss and serum level of Mg2+ 
is not an indicator of perilymphatic Mg2+ levels. The perilymphatic level may be low while the 
serum level is normal and most SSNHL patients have a normal range of serum Mg2+ levels. A 
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more reliable correlation may be found between perilymphatic and intracellular Mg2+ levels 
(Scheibe et al., 2000; Attias et al., 1994). 
Mg2+ treatment combined with carbogen in patients with SSNHL showed to improve 
significantly the hearing recovery compared with carbogen treatment alone. According to the 
literature, it is reported that spontaneous recovery in patients with SSNHL is about 50 to 70%. The 
results may also differentiate according to the criteria for recovery of each study (Gordin et al., 
2002). Nageris et al. (2004) used a prospective, randomized, double-blind placebo controlled trial 
to investigate the effectiveness of oral magnesium supplementation in the treatment of SSNHL. A 
significantly greater rate of recovery was reported among patients treated with steroids plus 
magnesium (n = 14) vs steroids plus placebo (n = 14) as measured 4 weeks after treatment. Group 
data analysis showed that the treatment group had a greater proportion of subjects with improved 
hearing thresholds at all test frequencies (F=4.8, p<0.02) and an overall greater mean improvement 
(F=3.7, P<0.05). Overall, according to these results it is suggested that magnesium 
supplementation can enhance steroid treatment of SSNHL. 
Gordin et al. (2002) completed a prospective, randomized, placebo-controlled trial to 
investigate the effectiveness of magnesium treatment for improving the outcome of unilateral 
SSNHL. There were 278 subjects diagnosed with SSNHL who were randomly assigned to either 
the control group, treated with carbogen inhalation or to the treatment group, treated with 
intravenous magnesium and carbogen inhalation. Subjects were later excluded from the control 
group for additional treatment (n=20) and from the treatment group due to side effects associated 
with magnesium (n=10) and several subjects were also lost from the control (n=59) and the 
treatment group (n=56) during follow-up procedures. Treatment continued until hearing was 
determined to be normal or similar to the better hearing ear using standard audiometric testing.  
For the purpose of their study, Gordin et al. (2002) defined recovery as an improvement 
rate greater than 75%. Recovery was achieved in 48% of the treatment group and 31.6% of the 
control group (p<0.01) and the mean improvement rate was reported as 66.4% in the treatment 
group and 49.9% in the control group (p<0.01). Overall, these results suggest that magnesium 
treatment may improve recovery in cases of SSNHL. 
Attias et al. (1994) conducted a prospective, randomized, double-blind, placebo-controlled 
trial to investigate the prophylactic value of long-term oral intake of magnesium in reducing noise-
induced permanent threshold shift. Male subjects (n=300) were randomly assigned to either the 
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control group, receiving a daily oral placebo treatment or to the treatment group receiving a daily 
oral magnesium supplement. All subjects experienced a similar lifestyle in terms of noise 
exposure, diet, and daily routine. Results revealed that the placebo group had significantly more 
frequent and severe permanent threshold shifts (x2=8.1, p<0.001). Overall, these results suggest 
magnesium supplementation may reduce noise-induced permanent hearing damage. 
Finally, Attias et al. (2004) evaluated the effects of magnesium intake on temporary 
threshold shift carrying a prospective, double-blind crossover study. Normal-hearing male subjects 
(n=20) participated in three measurement sessions: (1) a baseline measurement prior to any 
treatment, (2) a measurement 10 days after daily oral magnesium treatment, (3) a measurement 10 
days after daily placebo treatment. All subjects of the study were exposed to 90 dB Sound Pressure 
Level (SPL) white noise for a 10minute duration and audiometric evaluations were conducted prior 
to and after noise exposure until thresholds returned to normal. The results of this study suggest 
that magnesium supplementation can reduce noise-induced temporary threshold shift (Nageris et 
al, 2004; Gordin et al., 2002; Attias et al., 2004).  
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  CHAPTER 2  
TRIAL OBJECTIVES AND HYPOTHESES 
 
 
 
 
2.1 Objectives 
Primary 
 
 To evaluate efficacy of magnesium in combination with corticosteroids in the treatment of 
idiopathic sudden sensorineural hearing loss based on patients’ auditory system status. 
 To evaluate the safety and tolerability of magnesium in the treatment of idiopathic sudden 
sensorineural hearing loss. 
 
Secondary 
 
 To assess the efficacy of magnesium in combination with corticosteroids in the treatment 
of idiopathic sudden sensorineural hearing loss using the following methods  
o Laboratory blood tests. 
 Pure-tone threshold for air and bone conduction. 
 Pure-tone average (PTA). 
 Speech Discrimination Score (SDS). 
 Speech In Noise Testing (SINT). 
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 Tinnitus Severity Ranking Scale.  
(Gordin et al., 2002; Hain, 2016; Bednar et al., 2015) 
 
2.2  Endpoints 
Primary 
Efficacy: 
 Change from baseline to Tmax in Pure Tone Audiometry (PTA) averaged over 2 and 4 kHz; 
measured in the ear with the greater hearing deficit (determined at baseline). 
 
Safety: 
 Adverse Events, ECG, vital signs, safety laboratories. 
 
Secondary 
Efficacy: 
 Change from baseline in PTA averaged over 2 and 4 kHz; 
 Measured in the ear with the greater deficit (determined at baseline). 
 Change from baseline in SDS (Speech Discrimination Score) measured in the worst hearing ear as 
defined by PTA at baseline. 
 Change from baseline in SINT. 
 Change from baseline in Tinnitus Severity Ranking Scale  
 
(Bednar et al., 2015). 
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  CHAPTER 3  
TRIAL DESIGN 
 
 
 
 
This is a randomized, double-blind, placebo-controlled clinical trial assessing the 
therapeutic effect of magnesium aspartate, along with parallel administration of corticosteroids 
regarding patients diagnosed with unilateral idiopathic sudden sensorineural hearing loss. Subjects 
will receive 167 mg of magnesium aspartate or sodium aspartate (placebo) in 200ml of lemonade 
whereas both groups will be treated with 60 mg of corticosteroids per day, divided in three doses, 
for 15 days and taper therapy for one more week (Levie et al., 2007; Nageris et al., 2004). 
 
3.1  Details for the design of the trial  
The study will be divided into a screening period, a double-blind treatment period closing 
with a study end visit, and a post-treatment observation period. At the study end visit or at an early 
study medication discontinuation visit for premature discontinuation of study therapy, subjects 
will be transitioned from 60 mg of prednisone daily dosage to taper therapy for one week- 
decreasing dose 20 mg every 3 days. Patients may discontinue study drug for any of the following 
reasons: safety concerns, pregnancy, elevation of blood glucose levels on two consecutive 
measurements, severe hypotension or hypertension, noncompliance, or the need for an excluded 
medication.  
The time on study drug will vary from subject to subject depending upon the time of the 
subject’s enrollment.  Subjects will be qualified for the study within 2 days before randomization 
to allow adequate time for the site to review the inclusion and exclusion criteria for the prospective 
study participant. After meeting all study entry criteria, subjects will be randomized into treatment 
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groups and begin study drug treatment. The randomization will take place with the use of an 
Interactive Voice Response System (IVRS) and subjects will be randomly assigned in a 1:1 ratio 
to 1 of the following 2 treatment groups:  
 Magnesium aspartate 167mg in 200ml of lemonade per mouth once daily plus prednisone 60 mg per 
mouth divided in 3 daily doses of 20 mg for 2 weeks, following one more week of gradual decrease-
two daily doses of 20 mg of prednisone for 3 days, one daily dose of prednisone for 4 days.  
OR  
 Placebo sodium aspartate 167mg in 200ml of lemonade per mouth once daily plus prednisone 60 mg 
per mouth divided in 3 daily doses of 20 mg for 2 weeks, following one more week of gradual 
decrease-two daily doses of 20 mg of prednisone for 3 days, one daily dose of prednisone for 4 days 
(Attias et al., 1994). 
Once the subject’s eligibility for the study has been confirmed, the subject will after be 
randomized and study drug will be dispensed.  A 12-lead electrocardiogram (ECG), blood pressure 
measurement, audiometry and clinical laboratory tests will be performed every three days for the 
treatment period of 3 weeks. Subjects will return for visits after 4 weeks of the discontinuation of 
medication. 
All randomized subjects will be followed until the study ends (adjudicated endpoint events 
reached followed by study closure activities) even if they did not take study drug or prematurely 
discontinued study drug. Every effort should be made to contact any subjects lost in order to 
follow-up and collect information on the occurrence of efficacy endpoint events and the reason for 
discontinuation. When the pre-specified number of adjudicated primary efficacy endpoint events 
has been reached in the per protocol population, the sites will be notified by the sponsor to schedule 
each subject still receiving blinded study medication for a study-end-visit.  
The post-treatment observation period ends with a follow-up visit, which will be performed 
approximately 30 days after the study-end-visit. Subjects who have previously prematurely 
discontinued study drug will be contacted for a final assessment of efficacy endpoint events within 
30 days of site notification.  
An Executive Committee (EC) will be formed that has the overall responsibility for the 
conduct and reporting of the study. An independent Data Monitoring Committee (DMC) will be 
commissioned for this study, in order to monitor the progress of the study and to ensure that the 
safety of the subjects is not compromised. An independent blinded Clinical Endpoint Committee 
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(CEC) will apply the protocol definitions and adjudicate and classify the endpoints (Bednar et al., 
2015). 
 
3.2  Committees  
3.2.1  Executive Committee  
The EC consists of academic leadership members and one member from the possible 
sponsoring company. The EC will ultimately be responsible for the conduct of the study including 
addressing any Data Monitoring Committee recommendations and overseeing publication 
according to the results (Bednar et al., 2015). 
 
3.2.2  Steering Committee  
A Steering Committee will be formed consisting of members who are the lead investigators 
from each region. The Steering Committee will advise and assist the EC with regard to the 
scientific and operational aspects of the study (Bednar et al., 2015). 
 
3.2.3  Independent Data Monitoring Committee  
This study will be conducted under the auspices of an independent Data Monitoring 
Committee (DMC), which will ensure the safety of subjects enrolled in the study and monitor the 
progress of the trial. The DMC will consist of a chairperson, two otorhinolaryngologists, as well 
as a statistician. This committee will review on a regular basis the accumulating data, and may 
also request to review partially or totally unblinded accumulating data. The DMC will make 
recommendations to the Executive Committee regarding the continuing safety of subjects currently 
enrolled and yet to be enrolled in the trial. During the whole course of the study, the DMC may 
request access to unblinded data if needed (Bednar et al., 2015). 
 
3.2.4  Clinical Endpoint Committee  
The Clinical Endpoint Committee (CEC), composed of experts in the relevant fields, will 
review, in a blinded manner, all reported study outcomes in order to provide consistency and 
validity in the assessment of outcomes. Their decisions will be based on blind clinical data and 
will be used for the final statistical analyses (Clinical Research Resource HUB, 2015).   
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  CHAPTER 4  
ETHICAL CONSIDERATIONS 
 
 
 
 
4.1  Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) 
It is the investigator’s responsibility to have prospective approval of the study protocol, 
protocol amendments, informed consent documents, and other relevant documents, such as 
recruitment advertisements, if applicable, from the IRB/IEC. All correspondence with the IRB/IEC 
should be retained in the Investigator File.  
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval 
is where the change is necessary to eliminate apparent immediate hazards to the subjects. In that 
event, the investigator must notify the IRB/IEC (Bednar et al., 2015). 
 
4.2  Subject Information and Consent 
Protection of subject personal data has to be strictly ensured and so there will not be 
included subject names on any sponsor forms, reports, publications, or in any other disclosures, 
except where required by laws. 
Subject names, address, birth date and other identifiable data will be replaced by a 
numerical code consisting of a numbering system in order to de-identify the trial subject.  The 
informed consent document must be in compliance with International Council for 
Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and 
Good Clinical Practice (GCP), local regulatory requirements, and legal requirements. 
The informed consent document used in this study, and any changes made during the course 
of the study, must be prospectively approved by the IRB/IEC.  
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The investigator must ensure that each study subject, or his/her legal representative is fully 
informed about the nature and objectives of the study and possible risks associated with 
participation. 
The investigator will obtain written informed consent from each subject or the subject's 
legal representative before any study-specific activity is performed (Bednar et al., 2015). 
 
4.3  Subject Confidentiality  
Confidentiality must be preserved by investigators and all subjects taking part in the study, 
in accordance with GCP and local regulations.  
The Investigator must ensure the subject’s anonymity. On the electronic Case Report 
Forms (eCRFs) or other documents submitted to the Contract Research Organization (CRO), 
subjects should be identified by a unique subject identifier (Bednar et al., 2015). 
 
4.4  Subject Recruitment 
It is possible to use advertisements, approved by ethics committees and investigator 
databases, as recruitment procedures (Bednar et al., 2015). 
 
4.5  Ethical Conduct of the Study 
The study will be conducted in accordance with all legal and regulatory requirements, as 
well as the general principles set forth in the International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Council for International Organizations of Medical Sciences 
[CIOMS], 2002; Vijayananthan and Nawawi, 2008; World Medical Association, 2008). 
In addition, the study will be conducted in accordance with the protocol, the ICH guideline 
on GCP, and applicable local regulatory requirements and laws. 
 
4.6  Reporting of Safety Issues and Serious Breaches of the Protocol or ICH and 
GCP 
In the event of any prohibition or restriction by an applicable Competent Authority, or if 
the investigator is aware of any new information which might influence the evaluation of the 
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benefits and risks of the investigational product, the possible sponsor company should be informed 
immediately. 
In addition, a written report should immediately be prepared by the investigator, in case of 
any urgent safety measures taken in order to protect the study subjects against any immediate 
hazard, and of any serious breaches of this protocol or of ICH and GCP that the investigator may 
become aware of (Bednar et al., 2015). 
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  CHAPTER 5  
SUBJECT SELECTION 
 
 
 
 
There are certain eligibility criteria designed to select subjects for whom protocol treatment 
can be considered appropriate in order to fulfill the study objectives. All relevant medical and non-
medical conditions should be taken into consideration. 
 
5.1  Inclusion Criteria 
The subjects' eligibility criteria must be appropriately examined, reviewed and documented 
by a properly qualified member of the investigator’s study team before getting included in the 
study. 
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into 
the study: 
1. Evidence of a personally signed and dated informed consent document indicating the subject 
awareness of all pertinent aspects of the study. 
2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory 
tests, efficacy assessments, safety assessments, and other study necessary procedures. 
3. Male, and female subjects of non-childbearing potential who are 20-65 years of age and a 
body weight of at least 50 kg. 
4. Subjects who can read, speak and comprehend Greek or English. 
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5. Subjects must have a current diagnosis of unilateral idiopathic sudden sensorineural hearing 
loss which has occurred within the last 72 hours in the range of 30-60 dB (inclusive), 
averaged over 2 and 4 kHz in at one ear. The Pure Tone Audiometry (PTA) assessment will 
provide the basis of the diagnosis.  
6. Subjects must have symmetric hearing loss with respect to both PTA and Speech 
Discrimination score (SDS). 
7. Subjects who are hearing aid users will be allowed but subjects will refrain from wearing the 
hearing aid on the day of drug administration and for at least 24 hrs after procedure visits 
(Bednar et al., 2015; Plontke et al., 2009). 
 
5.2  Exclusion Criteria 
Subjects presenting with any of the following will be excluded from the study: 
1. Pregnant females and breastfeeding females. 
2. Subjects with a history of sudden hearing loss and diagnosis of rapidly progressive idiopathic 
hearing loss. 
3. Subjects who have the following hearing disorders or any other hearing disorders that may 
impact efficacy assessments or safety of subjects in the opinion of the investigator: 
Meniere’s disease (history or present), concurrent vestibular pathology, radiation-induced 
hearing loss, endolymphatic hydrops, suspected retro-cochlear lesion or fluctuating hearing 
loss; history of asymmetric hearing loss, conductive hearing loss (defined as Bone 
Conduction – Air Conduction), prior ear surgery (except ventilating tubes), congenital 
hearing loss, genetic SSNHL with strong family history, active otitis externa or media, 
cochlear ossification, cholesteatoma or otosclerosis. 
4. Subjects with moderate or greater tinnitus as indicated by a Tinnitus Handicap Inventory 
Score of 38. 
5. Subjects with a speech discrimination score obtained at the screening visit of <60% in either 
ear. 
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6. Subjects with systemic diseases that could affect hearing or hearing assessment, such as a 
history of autoimmune disease (e.g. rheumatoid arthritis, lupus, etc.), myasthenia Gravis, 
myopathy, dementia, hyperadrenocorticalism, hyperlipidemia, electrolyte imbalance, 
osteoporosis, (+) tuberculin test. 
7. Subjects on prohibited medications and not able to discontinue these concomitant 
medications after the screening visit. Subjects taking concomitant-medications that can 
effect hearing, including but not limited to systemic steroids, aminoglycosides, ototoxic 
chemotherapeutic drugs taken at any time in the past (e.g., cis-platinum). Subjects taking 
concomitant-medications that may affect the pharmacokinetics of the drug will be excluded. 
8. Current (past 2 weeks prior to screening) pathological noise exposure either due to 
occupational, recreational, or other types of noise exposure (e.g. 1) occupational noise in 
professions requiring regular use of hearing protection, 2) target shooting/firing range 
exposure, 3) hunting, etc.). 
9. Subjects with a cochlear implant. 
10.  Subjects with evidence or history (referring to the current timeframe) of clinically significant 
cardiovascular disease, including uncontrolled hypertension (sitting or supine diastolic 
pressure >95 mm Hg and/or sitting or supine systolic pressure >170 mm Hg with or without 
treatment), hypotension, bypass surgery, history of myocardial infarction or ischemic heart 
disease, uncompensated heart failure or recent acute myocardial infarction, as determined by 
the investigator. Controlled essential hypertension and non-clinically significant sinus 
bradycardia and sinus tachycardia will not be considered significant medical illnesses and 
would not exclude a subject from the study. 
11.  Subjects with a medical history of glaucoma, ocular herpes simplex and ototoxicity. 
12.  Subjects who are known to have AIDS or to be HIV positive. 
13.  Subjects with screening laboratory test results that deviate from the upper or lower limits of 
the reference range, except for not clinically significant values, as determined by the 
investigator. 
14.  Subjects with a 12-lead ECG with repeated demonstration of QTcF >450 msec at screening 
or at baseline (Day 1) based on the automated machine reading. 
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15.  Any condition possibly affecting drug absorption (e.g., gastrectomy). 
16.  For subjects with a high risk assessment done by a qualified mental health professional to 
assess whether it is safe for the subject to participate in the study. In addition, subjects 
deemed by the investigator to be at significant risk of suicidal or violent behavior should be 
excluded. 
17.  Subjects who have taken an investigational drug within 30 days prior to baseline. 
18.  Participation in other interventional/investigational drug studies within 30 days before the 
current study begins and/or during study participation. 
19.  Blood donation in the 60 days prior to the screening visit or any subject planning to donate 
blood during the course of the clinical trial. 
20.  Subjects who have presbycousis. 
21.  Unwilling or unable to comply with the Life Style Guidelines described in this protocol. 
22.  Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that 
may increase the risk associated with study participation or investigational product 
administration or may interfere with the interpretation of study results and, in the judgment 
of the investigator, would make the subject inappropriate for entry into this study. 
23.  History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 oz. of wine 
[150mL] or 12 oz. [360 mL] of beer or 1.5 oz. [45 mL] of hard liquor) within 6 months of 
Screening. 
24.  Subjects who are smokers whose smoking pattern would prevent them from completing the 
Screening or Treatment period assessments without nicotine withdrawal symptoms. 
25.  Subjects who are investigational site staff members or their relatives or subjects who are 
directly involved in the conduct of the trial. 
(Bednar et al., 2015; Plontke et al., 2009). 
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5.3  Life Style Guidelines 
5.3.1  Meals and Dietary Restrictions 
It is necessary that subjects will have abstained from food and drink at least 3 hours prior 
to the Screening safety laboratory evaluations. There is a dietary restriction regarding sugar and 
salt.  
 
5.3.2  Alcohol, Caffeine and Tobacco 
Subjects must abstain also from alcohol for 24 hours prior to admission to the study site. 
Alcohol consumption will not exceed 14 drinks/week  throughout the study. Subjects may undergo 
an alcohol breath test at the discretion of the investigator. Subjects will limit caffeine in coffee, tea 
and/or other caffeine-containing beverages, food or drugs to no more than an average of 300 mg 
of caffeine/day within observation and treatment periods (~2-3 cups coffee, ~6 cans soda). 
Subjects will abstain from the use of tobacco- or nicotine-containing products for 3 hours prior to 
dosing (Bednar et al., 2015). 
 
5.3.3  Activity 
Subjects must abstain from strenuous exercise for at least 48 hours prior to blood collection 
for clinical laboratory tests for all visits (Bednar et al., 2015). 
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  CHAPTER 6  
RANDOMIZATION AND BLINDING 
 
 
 
 
6.1  Randomization and Blinding 
Central randomization will be implemented in conducting this study. At the time of 
enrollment, each subject will be assigned a unique sequential subject number by the IVRS 
(interactive voice response system) and a treatment code, which will dictate the treatment 
assignment for that subject. The IVRS will be available 24 hours per day, seven days a week. The 
subject number will consist of a unique 5 digit number which is assigned sequentially within the 
study (starting with 00001) by the IVRS. This number will be used for identification throughout 
the study and will not be used for any other subject. Subjects will be randomly assigned in a 1:1 
ratio (magnesium aspartate plus prednisone to sodium aspartate plus prednisone) to either 
treatment or control groups and the randomization will be stratified by age groups and first 
audiometric results. So the IVRS will then also assign a medication kit (and subsequent medication 
kits) that matches the treatment code to which the subject has been randomized.  
The investigator will not be provided with randomization codes. The codes will be 
maintained within the IVRS, which has the functionality to allow the investigator to break the 
blind for an individual subject.  
This study has a double-blind design. Neither the subjects nor any of the Investigators or 
Sponsor staff involved in the treatment or clinical evaluation of the subjects will be aware of the 
treatments received. There will be an independent DMC to monitor the data (audiometry, 
laboratory tests) in an unblinded manner on a periodic basis. An independent statistician, not 
otherwise involved in the study, will prepare and provide the required reports to the DMC.  
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The blind should be broken only if specific emergency treatment would be dictated by 
knowing the treatment status of the subject. If for any reason, the Investigator needs to become 
unblinded to the treatment of a subject, he/she will make every attempt to first call the sponsor and 
discuss the need for unblinding and obtain agreement. If the investigator is unable to contact the 
sponsor, the investigator may in an emergency determine the identity of the treatment by 
telephoning IVRS. The sponsor must be informed as soon as possible by the investigator. Efforts 
should be made to limit access to knowledge of the treatment assignment to only those individuals 
who need to know the information and the subject should continue in the study.  
Magnesium aspartate and its matching placebo will be taken once daily as a fixed dose of 
200 ml of lemonade containing 167 mg of magnesium or sodium aspartate respectfully. Prednisone 
will be administered to both study groups in three daily doses of 20mg. The age and first 
audiometry results will be embedded in a “code number” and reported to a central IVRS along 
with the subject's study identification number.  
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  CHAPTER 7  
STUDY PROCEDURES AND ASSESSMENTS  
 
 
 
 
In cases that circumstances, outside of the control of the investigator, may make it 
unfeasible to perform the tests, the investigator will take all steps necessary to ensure the safety 
and the well-being of the subjects. When a protocol required test cannot be performed the 
investigator must document the reasons for this and any corrective and preventive actions which 
he/she has taken to ensure that normal processes are adhered to as soon as possible. 
 
Blood Volume 
Total blood sampling for the individual subjects is approximately 134 ml. Additional blood 
samples may be taken for safety assessments and the IRB is notified of the blood collection. 
 
7.1  Screening Period 
Subjects need to be screened prior to administration of the study medication in order to 
confirm that they meet the subject selection criteria for the study. The investigator will obtain 
informed consent from each subject according to the procedures described.  
The following procedures must be completed (Bednar et al., 2015; Lawrence et al., 2015; 
Schweinfurth et al., 1997; Nageris et al., 2003): 
 
 Obtain written informed consent. 
 Review inclusion and exclusion criteria. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:07:29 EET - 137.108.70.7
35 
 
 Complete medical history including neurological, psychiatric and hearing loss history. 
 Full physical and neurological examination. 
 Height and weight. 
 Complete history of all prescription or nonprescription drugs, and dietary and herbal supplements 
taken within 28 days prior to the planned first dose. 
 History of drug, alcohol and tobacco use. 
 Review history of medical devices including hearing aid use. 
 Verify noise exposure within the past 2 weeks due to occupational, recreational, or other types of 
noise exposure including but not limited to jackhammers, jet engines, firing ranges, etc. 
 Oral temperature. 
 Supine and standing blood pressure and pulse rate. 
 Singlet 12-lead electrocardiogram (ECG). 
Following at least a 3-hour fast, blood and urine specimens will be collected for the 
following: 
 Safety laboratory tests (chemistry, hematology and urinalysis). 
 Urine drug screen. 
 Administer Mini Mental State Examination (MMSE). 
 Administer the Patient Health Questionnaire-8 (PHQ-8). 
 Suicidality Monitoring: administer Columbia Suicide Severity Rating Scale (C-SSRS) 
Baseline/Lifetime Assessment. 
 Administer Tinnitus Handicap Inventory before audiology assessments. 
 Perform Pure Tone Average (PTA) assessment. 
 Speech Discrimination Score (SDS). 
 Brain Magnetic Resonance Imaging (MRI) to exclude the presence of tumors such as an 
acoustic neuroma.  
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Before any audiometric assessments the audiologist will first examine the ears with an 
otoscope and in case that significant cerumen is occluding the canal, the cerumen must be removed 
prior to study participation. All the potential subjects will have the study risks and benefits 
explained in detail to them, the associated International Classification of Functioning, Disability, 
and Health (ICF) reviewed with them, and all questions answered for them. Screening procedures 
will be performed within 2 days before randomization. The investigator should obtain relevant 
medical history and vital signs and perform physical examination. The results of all screening 
procedures must be reviewed before randomization to ensure that all inclusion criteria and none of 
the exclusion criteria are met.  
 
7.2  Treatment period 
Subjects entering the study will be administered orally 20mg of prednisone tablets 3 times 
per day, for 2 weeks. The last dose will not be administered later than 8 pm. After the first two 
weeks of the study High Dose Prednisone Taper (HDPT) therapy will follow for one more week.  
Laboratory tests, vital signs and audiometric examination will be followed every three days of the 
study. 
 
7.3  Post-treatment observation period- follow-up visit  
After the study end visit or Study drug discontinuation visit, there will be an observation 
period to follow subjects after transition. Subjects will be asked to return to the clinic for a follow-
up visit approximately 30 days after the permanent discontinuation of study drugs.  
At the follow-up visit the Investigator will:  
 Assess for Serious Adverse Events (SAEs) (until 30 days after the last dose of double-blind 
study drugs).  
 Assess for outcomes (laboratory test results, audiometric results).  
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7.4  Subject Early Termination/Withdrawal 
It is possible for subjects to withdraw from the study at their own request, or they may be 
withdrawn at any time at the discretion of the investigator or sponsor for safety or behavioral 
reasons, or the inability of the subject to comply with the protocol required schedule of visits and 
procedures. In case of a subject does not return for a scheduled visit, every effort should be made 
to contact the subject. The investigator should inquire about the reason for withdrawal, request the 
subject to return all unused investigational product(s), request the subject to return for a final visit, 
if applicable, and follow-up with the subject regarding any unresolved adverse events. 
If a subject withdraws during a treatment period, the subject should be scheduled for a final 
follow up visit within 30 days of the last dose of study treatment. Assessments may include: 
 Obtain information regarding the use of concomitant medications. 
 Brief neurological examination. 
 Collect a blood sample for pharmacokinetic. 
 Verification of noise exposure within the past 2 weeks due to occupational, recreational, or other 
types of noise exposure including but not limited to jackhammers, jet engines, firing ranges, etc. 
 Supine and standing blood pressure and pulse rate. 
 Safety laboratory tests (chemistry, hematology and urinalysis). 
 Assess symptoms by spontaneous reporting of adverse events and by asking the subjects to respond 
to a non-leading question such as “How do you feel?” 
 Discharge from study. 
 
If the subject withdraws from the study, and also withdraws consent for disclosure of any 
future information, no further evaluations should be performed, and no additional data should be 
collected. Subjects who withdraw from the study can be replaced at the according to the 
investigator upon consultation with the sponsor (Bednar et al., 2015). 
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7.5  Efficacy Assessments 
7.5.1  Pure Tone Audiometry/Pure Tone Average (PTA) 
The most common procedure for the measurement of hearing loss is pure tone audiometry 
is. The tones with a single frequency of vibration, which are called pure tone signals, are delivered 
to the subject via insert earphones and a bone vibrator. At the screening visit, air and bone 
conduction audiometry will be performed. Air conduction audiometry will be performed with 
insert earphones and thresholds will be obtained at 0.25, 0.5, 1, 2, 4, and 8 kHz. Bone conduction 
audiometry will assess thresholds at 0.5, 1, 2, and 4 kHz tones. The air-bone gap, which is defined 
as the comparison of air-conduction and bone-conduction thresholds, helps to characterize the type 
of hearing loss. For study visits, only air conduction audiometry will be performed at baseline and 
at post-dosing assessments. Audiometric thresholds will be assessed the times specified in this 
protocol (Bednar et al., 2015). 
 
7.5.2  Speech Discrimination Score (SDS) 
The Speech Discrimination Score (SDS) presents monosyllabic words, phonetically 
balanced at above the speech reception threshold (SRT) intensities or a Pure Tone Average (PTA) 
of 0.5, 1, and 2 kHz tones and measures speech comprehension through. Maximal speech 
discrimination scores are typically seen at SRT or PTA plus 25-40 dB. Results are expressed as a 
percentage of words repeated correctly. For the Screening assessments only, the SDS will be 
measured independently in the right and left ear using one-half of a 50-word list of Consonant-
Nucleus-Consonant (CNC) words presented at 25-40 dB above the pure tone average of 0.5, 1, 
and 2 kHz tones. The level of presentation will be based on the audiologist’s discretion regarding 
subject comfort level. Subjects with SDS scores in either ear of <60% at screening will be 
ineligible for the study. Also, SDS should be symmetric, meaning that the difference in SDS 
between ears should be <20%, since a greater difference may be associated with 
pathophysiological processes that could affect efficacy endpoints (Bednar et al., 2015). 
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7.5.3  Speech in Noise Testing (SINT) 
A direct measurement of functional speech perception in noise in the sound field utilizing 
both ears at once will be performed using Arizona BioIndustry Association (AZBio) Sentences. 
AZBio scores will only be measured under the condition of Multitalker Babble noise presented 
from the front. Each subject will be administered one list of AZBio Sentences in Quiet at 60 dB 
SPL. The % correct score is computed and half of that will be denoted as a Target Score. Testing 
is continued at various signal to noise ratios (-10, -7, -4, -1, +2, +5, +8, +11) in which the speech 
input is kept constant at 60 dB SPL, and the Multitalker babble noise is set to the test ratio to 
determine the Target Signal to Noise Ratios (SNR) (the level at which the subject obtains a percent 
correct score within 9% of the Target Score). Each test repetition at a particular SNR will involve 
the use of one list of AZBio sentences.  There are 8 lists of AZBio Sentences which will be 
administered at baseline and two specific time points at each period. To reiterate subjects will be 
administered one list of AZBio Sentences in Quiet at 60 dB SPL which will be used to generate 
the Target Score. Testing will continue at various SNR in which the speech input is kept constant 
at 60 dB SPL, and the Multitalker babble noise is set to the test ratio to determine the Target SNR.  
The SINT will be assessed as per times specified in this protocol (Bednar et al., 2015). 
 
7.5.4  Tinnitus Handicap Inventory 
The Tinnitus Handicap Inventory is a self-report questionnaire that lists subjective 
questions designed to identify problem areas that may be present if a subject is distressed by the 
possible presence of tinnitus. Questions include targeting of emotions (i.e., depression, anxiety), 
limitations and generally the inability to cope. The Tinnitus Handicap Inventory will be assessed 
before the subject performs the audiology assessments at the Screening visit. The Tinnitus 
Handicap Inventory will be assessed as specified in this protocol (Bednar et al., 2015). 
 
7.5.5  Tinnitus Severity Ranking Scale 
The Tinnitus Severity Ranking Scale is a self-report measure of tinnitus distress severity 
utilizing a scoring system from 1-10 to reflect changes in tinnitus distress over time (Bednar et al., 
2015). 
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7.6  Safety 
7.6.1  Laboratory 
The following safety laboratory tests will be performed at the time points specified in this 
protocol: 
 Hemoglobin 
 Hematocrit 
 RBC count 
 Platelet count 
 WBC count 
 Total neutrophils  
 Eosinophils  
 Monocytes  
 Basophils  
 Lymphocytes  
 MCH 
 MCHC 
 MCV 
 Reticulocyte count 
 Creatinine 
 Glucose  
 Urea 
 Ca++ 
 Na+, K+, Cl- 
 Total CO2 (Bicarbonate) 
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 AST, ALT 
 Total Bilirubin 
 Alkaline phosphatase 
 Uric acid 
 Albumin 
 Total protein 
 Creatine Kinase 
 pH 
 Urine Drug Screen 
 Safety laboratory tests from Screening, as judged by the Investigator, must have no 
clinically significant findings, in order for a subject to be enrolled in the study. 
 Urine drug screening will be performed with minimum requirement for drug screening 
including: cocaine, Tetrahydrocannabinal (THC), opiates, benzodiazepines and amphetamines. 
Subjects may undergo random urine drug testing at the discretion of the investigator. Drug testing 
conducted prior to dosing must be negative for subjects to receive study medication (Bednar et al., 
2015). 
 
7.6.2  Blood Pressure and Pulse Rate 
Blood pressure (BP) and pulse rate will be measured at certain time points. Supine blood 
pressure will be measured with the subject's arm supported at the level of the heart, and recorded 
to the nearest mm Hg after 5 minutes of rest. The same arm will be used throughout the study 
(Bednar et al., 2015). 
 Single supine and standing blood pressure and pulse rate will be measured at times 
specified in this protocol. 
 Subject in supine position for a minimum of 5 minutes. 
 Stand subject up for 3 minutes. 
 Assess BP immediately after 3 minutes in standing position.  
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7.6.3  Electrocardiogram (ECG) 
A triplicate and single 12-lead ECG will be collected as scheduled in this protocol. All 
scheduled ECGs should be performed after the subject has rested quietly for at least 10 minutes in 
a supine position. The investigator is responsible for reviewing machine interpretations and for 
retaining hard copies of the ECG tracings and reports and the documentation of time and date of 
the ECG performance. Any clinically important findings will be noted in the CRF. The centrally 
reported ECG results will be used in the study analysis. In some cases, it may be appropriate to 
repeat abnormal ECGs to rule out improper lead placement as contributing to the ECG abnormality 
(Bednar et al., 2015). 
 
7.6.4  Physical Examination 
The complete physical examination will evaluate any clinically important abnormalities 
within the body systems (e.g., skin, head/eyes/ears/nose/throat, neck, heart, lungs, abdomen, 
musculoskeletal system and lymph nodes) (Bednar et al., 2015). 
 
7.6.5  Neurological Examination 
A full neurologic examination will be completed including level of consciousness, speech, 
cranial nerves (including pupil equality and reactivity), motor function, sensory function, 
coordination, gait, and reflexes. Identification of any pre-existing movements should be 
emphasized for comparison to post-dosing examinations. Observation for movements should focus 
on an approximately 15 second observation period for any given anatomic area. Clinically 
important abnormalities and any movements observed at the screening visit should be noted on 
source documents and/or the medical history.  
The brief neurological exam will include observation for cerebellar (intention) tremor and 
for non-cerebellar tremors (resting), finger nose, heel shin, Romberg, tandem walking, and 
spontaneous and gaze-evoked nystagmus (Bednar et al., 2015). 
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7.6.6  Mini Mental State Examination (MMSE) 
The MMSE is a brief, widely used test for assessing overall cognitive state. The MMSE 
measures selected aspects of cognition such as memory, orientation, attention, language, and 
praxis on a scale of 0 to 30. Lower scores indicate greater cognitive impairment. The MMSE will 
be performed only during Screening (Bednar et al., 2015). 
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  CHAPTER 8  
ADVERSE EVENT REPORTING  
 
 
 
 
8.1  Adverse Events 
For all Adverse Events (AEs), the investigator must pursue and obtain information 
adequate both to determine the outcome of the AE and to assess whether it meets the criteria for 
classification as an SAE requiring immediate notification to the trial’s designated representative. 
For all AEs, it is necessary that sufficient information is obtained by the investigator in order to 
determine the causality of the AE. Causality is assessed by the investigator and follow-ups may be 
required until the event resolve or stabilize. 
As part of ongoing safety reviews conducted by the Sponsor, any non-serious adverse event 
that is determined by the Sponsor to be serious will be reported by the Sponsor as an SAE. 
To assist in the determination of case seriousness further information may be requested 
from the investigator to provide clarity and understanding of the event in the context of the clinical 
trial (Bednar et al., 2015). 
 
8.2  Reporting Period 
For SAEs, the active reporting period begins from the time that the subject provides 
informed consent, which is obtained prior to the subject’s participation in the study, ie, prior to 
undergoing any study-related procedure and/or receiving investigational product, through and 
including 28 calendar days after the last administration of the investigational product. Should an 
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investigator be made aware of any SAE occurring any time after the active reporting period, it 
must be promptly reported. AEs (serious and non-serious) should be recorded on the CRF from 
the time the subject has taken at least one dose of study treatment through last subject visit (Bednar 
et al., 2015). 
 
8.3  Definition of an Adverse Event 
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a specific product or medical device when the event does not necessarily have a 
causal relationship with the treatment or usage. Examples of AEs include but are not limited to 
(Bednar et al., 2015): 
 
 Abnormal test findings; 
 Clinically significant symptoms and signs; 
 Changes in physical examination findings; 
 Hypersensitivity; 
 Progression/worsening of underlying disease; 
 Drug abuse; 
 Drug dependency. 
Additionally, they may include the signs or symptoms resulting from: 
 Drug overdose; 
 Drug withdrawal; 
 Drug misuse; 
 Drug interactions; 
 Extravasation; 
 Exposure during pregnancy; 
 Exposure via breast feeding; 
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 Medication error. 
 
8.4  Abnormal Test Findings 
The criteria for determining whether an abnormal objective test finding should be reported 
as an AE are as follows: 
 Test result is associated with accompanying symptoms, and/or 
 Test result requires additional diagnostic testing or medical/surgical intervention, and/or 
 Test result leads to a change in study dosing or discontinuation from the study, significant 
additional concomitant drug treatment, or other therapy, and/or 
 Test result is considered to be an AE by the investigator or sponsor. 
 
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an AE. Any abnormal test result that is determined to be an error does not require 
reporting as an AE (Bednar et al., 2015). 
 
8.5  Serious Adverse Events 
An SAE is any unexpected medical occurrence that: 
 Results in death 
 Is life-threatening  
 Requires patient hospitalization or prolongation of hospitalization 
 Results in persistent or significant disability/incapacity  
 Results in congenital anomaly/birth defect. 
 
An important medical event may not be immediately life-threatening and/or result in death 
or hospitalization. However, if it is determined that the event may jeopardize the subject or may 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:07:29 EET - 137.108.70.7
47 
 
require intervention to prevent one of the other AE outcomes, the important medical event should 
be reported as serious (Bednar et al., 2015). 
 
8.5.1  Potential Cases of Drug-Induced Liver Injury 
Abnormal values in aspartate transaminase (AST) and/or alanine transaminase (ALT) 
concurrent with abnormal elevations in total bilirubin that meet the criteria outlined below in the 
absence of other causes of liver injury are considered potential cases of drug-induced liver injury 
and should always be considered important medical events. 
Subjects who may present with the abnormal laboratory abnormalities should be further 
evaluated further in order to determine the exact etiology of the abnormal laboratory values. 
For subjects with pre-existing values of total bilirubin above the normal range: Total 
bilirubin increased by one time the upper limit of normal or 3 times the upper limit of normal. 
The subject must return to the investigational site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the abnormal results. This evaluation should include 
laboratory tests, detailed history and physical assessment. In addition to repeating AST and ALT, 
laboratory tests should include albumin, creatine kinase, total bilirubin, direct and indirect 
bilirubin, gamma-glutamyl transferase, prothrombin time (PT) and alkaline phosphatase. A 
detailed history, including relevant information, such as review of ethanol, acetaminophen, 
recreational drug and supplement consumption, family history, occupational exposure, sexual 
history, travel history, history of contact with a jaundiced subject, surgery, blood transfusion, 
history of liver or allergic disease, and work exposure, should be collected. 
Further testing for acute hepatitis A, B, or C infection and liver imaging may be warranted 
(Bednar et al., 2015). 
 
8.6  Hospitalization 
AEs reported from studies associated with hospitalization or prolongations of 
hospitalization are considered serious. In case of any initial admission (even if less than 24 hours) 
to a healthcare facility meets these criteria.  
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Hospitalization or prolongation of hospitalization in the absence of a precipitating, clinical 
AE is not in itself an SAE. Examples include: 
 Admission because of a preexisting condition not associated with the development of an 
AE  
 Social admission  
 Administrative admission  
 Protocol-specified admission during a study  
 Optional admission not associated with a precipitating clinical AE  
 Hospitalization for observation without a medical AE 
 
Pre-planned treatments or surgical procedures should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject (Bednar et al., 2015). 
 
8.7  Severity Assessment 
If required on the AE case report forms (CRFs), the investigator may use the categories 
MILD, MODERATE, or SEVERE to describe the intensity of the AE. For purposes of consistency, 
these intensity grades are defined as follows: MILD does not interfere with subject's usual function. 
MODERATE interferes to some extent with subject's usual function. SEVERE interferes 
significantly with subject's usual function. Note the distinction between the severity and the 
seriousness of an AE. A severe event is not necessarily also a SAE (Bednar et al., 2015). 
 
8.8  Causality Assessment 
The investigator’s assessment of causality must be provided for all AEs (serious and non-
serious) and the causal relationship in the CRF, must be recorded as appropriate. An investigator 
has also to causality assessment is the determination of whether there exists a reasonable 
possibility that the investigational product caused or contributed to an AE; generally the facts 
(evidence) or arguments to suggest a causal relationship should be provided. If the investigator 
does not know whether or not investigational product caused the event, then the event will be 
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handled as “related to investigational product” for reporting purposes, as defined by the Sponsor. 
If the investigator's causality assessment is "unknown but not related to investigational product", 
this should be clearly documented on study records. In addition, if the investigator determines an 
SAE is associated with study procedures, the investigator must record this causal relationship in 
the source documents and CRF, as appropriate, and report such an assessment in accordance with 
the SAE reporting requirements, if applicable (Bednar et al., 2015). 
 
8.9  Exposure during Pregnancy 
If a study subject becomes or is found to be pregnant during the study subject’s treatment 
with the investigational product, or directly after discontinuing it, the investigator must submit this 
information, irrespectively of whether an AE has occurred and within 24 hours of awareness of 
the exposure. The investigator will follow the pregnancy until completion or termination and notify 
of the outcome. In the case of a live birth, the structural integrity of the neonate can be assessed at 
the time of birth. In the event of a termination, the reason(s) for termination should be specified. 
If the outcome of the pregnancy meets the criteria for an SAE (i.e., ectopic pregnancy, spontaneous 
abortion, intrauterine fetal demise, neonatal death, or congenital anomaly, the investigator should 
follow the procedures for reporting SAEs. 
 
Additional information about pregnancy outcomes that are reported as SAEs follows: 
 Spontaneous abortion includes miscarriage and missed abortion; 
 Neonatal deaths that occur within 1 month of birth should be reported, without regard to 
causality, as SAEs.  
 
Additional information regarding the exposure during pregnancy may be requested by the 
investigator. Further follow-up of birth outcomes will be handled on a case-by-case basis (Bednar 
et al., 2015). 
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8.10  Withdrawal Due to Adverse Events  
Withdrawal may take place either due to an AE or due to insufficient response and in the 
case that a subject withdraws due to an SAE, the SAE must be reported in accordance with the 
reporting requirements defined below (Bednar et al., 2015). 
 
 
8.11  Eliciting Adverse Event Information 
The investigator is responsible for documenting and reporting all directly observed AEs 
and all AEs spontaneously mentioned by the study subject. In addition, each study subject will be 
questioned about AEs (Bednar et al., 2015). 
 
8.12  Reporting Requirements 
Each AE is to be assessed to determine if it meets the criteria for SAEs. If an SAE occurs, 
expedited reporting will follow local and international regulations, as appropriate (Bednar et al., 
2015). 
 
8.12.1  Serious Adverse Event Reporting Requirements 
If an SAE occurs, it must be notified within 24 hours to the investigator. In particular, if 
the SAE is fatal or life-threatening, notification must be made immediately, irrespective of the 
extent of available AE information. This timeframe also applies to any additional new information 
(follow-up) on previously forwarded SAE reports as well as to the initial and follow-up reporting 
of exposure during pregnancy and exposure via breast feeding cases. 
In the case that the investigator does not become aware of the occurrence of an SAE 
immediately, he has to report it within 24 hours after learning of it and document the time of his/her 
first awareness of the AE. 
In addition, an investigator may be requested to obtain specific additional follow-up 
information, which, in general, will include a description of the AE in sufficient detail to allow for 
a complete medical assessment of the case and independent determination of possible causes. 
Information on other possible causes of the event, such as concomitant medications and illnesses 
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must be provided. In the case of a subject death, a summary of available autopsy findings must be 
submitted as soon as possible (Bednar et al., 2015). 
 
8.12.2  Non-Serious Adverse Event Reporting Requirements 
All AEs will be reported on the AE section of the CRF. AEs should be reported using 
concise medical terminology on the CRFs as well as on the form for collection of SAE information 
(Bednar et al., 2015). 
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  CHAPTER 9  
INFORMATION ABOUT TREATMENTS 
ADMINISTERED  
 
 
 
 
9.1  Allocation to Treatment 
Investigators will use an Interactive Response System (IRS) to in order to assign a unique 
subject identification number sequentially to each subject who has signed the Informed Consent 
Document (ICD). This identifying number is going to be retained throughout the duration of the 
study participation. Subject eligibility for participation in the active treatment phase of the protocol 
will be determined following the assessments on Day 1 (Baseline). The investigator will obtain a 
randomization number and study medication assignments utilizing the IRS. The randomization 
number will be recorded once in the CRF. The subject will receive the appropriate study 
medication as assigned by the IRS (Bednar et al., 2015). 
 
9.2  Breaking the Blind 
Since the study will be double-blinded, the study drug will be administered to each subject 
according to the randomization schedule and protocol by a third party, not involved in the study 
In order to maintain the double-blinded conditions of the study.  
The subject and investigator will be blinded to whether the subject receives magnesium 
aspartate or placebo sodium aspartate during any given period. In order to have an ensured 
accuracy of the study drug treatment, an unblinded monitor will perform study drug accountability 
and reconciliation procedures, who is going to remain blinded to all other study data. All other 
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study personnel will be blinded to the identity of the study drug including a blinded monitor who 
will remain blinded to treatment until all monitoring for the study has been completed.  
To minimize the potential for bias, treatment randomization information will be kept 
confidential by specific personnel and will not be released to the investigator or investigator site 
personnel until the study database has been locked. 
At the initiation of the study, the study site will be instructed on the method for breaking 
the blind. Blinding codes should only be broken in emergency situations for reasons of subject 
safety. In any case, when the blinding code is broken, the reason must be fully documented and 
entered on the case report form (CRF) (Bednar et al., 2015). 
 
9.3  Drug Supplies 
9.3.1  Formulation and Packaging 
The magnesium aspartate and the placebo sodium aspartate diluted in lemonade oral 
solutions will be supplied by the sponsor and presented to the subjects in individual dosing 
containers at the Clinical Research Unit. The study may additionally utilize a central pharmacy for 
preparation of magnesium and placebo oral solution for some or all of the study sites. The 
prednisone oral dosing will also be dispensed at the Clinical Research Unit (Bednar et al., 2015). 
 
 
9.3.2  Preparation and Dispensing 
Magnesium and placebo oral dosing solutions will be prepared in the Clinical Research 
Unit by 2 operators, one of whom being necessarily a qualified pharmacist. Details of dose 
preparation and appropriate storage conditions for the solutions will be given in separate 
Extemporaneous Dispensing Record (EDR). For achieving the ensured accuracy of the study drug 
treatment, an unblinded monitor will perform study drug accountability and reconciliation 
procedures (Bednar et al., 2015). 
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9.3.3  Administration 
Investigator site personnel will dispense study medication at visits as specified in the EDR. 
Dosing should occur from approximately 7 am to 8 pm. Medication errors are reportable 
irrespective of the presence of an associated AE/SAE, including: 
 Medication errors involving subject exposure to the product. 
 Potential medication errors not foreseen in the protocol. 
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error must be captured on an adverse event (AE) CRF page. In the 
event of medication dosing error, the sponsor should be notified immediately (Bednar et al., 2015). 
 
9.3.4  Compliance    
All doses of study drug will be prepared by a study pharmacist and administered by study 
staff. The records of the pharmacy subject chart must document the composition and 
administration, respectively, of study drug for each subject at each dose. Date and time of 
administration will be recorded in the subject chart. A second site staff member should confirm 
documentation of records. This confirmation should be documented in each subject chart (Bednar 
et al., 2015). 
 
9.4  Drug Storage and Drug Accountability 
The investigator, or an approved representative, e.g., pharmacist, must ensure that all 
investigational product is stored in a secured area under recommended storage conditions and in 
accordance with applicable regulatory requirements. Storage conditions stated in the Investigator 
Brochure (IB), Core Data Sheet (CDS), United States Package Insert (USPI), Summary of Product 
Characteristics (SPC), or Local Product Document (LPD) may be superseded by the label storage. 
All study drugs will be accounted for via the drug accountability forms. For any deviations from 
the recommended storage conditions, the sponsor should be notified and the material placed in 
quarantine until an appropriate assessment can be made of the deviation. At the end of the study, 
Sponsor will provide instructions as to disposition of any unused investigational product. 
Investigators and site staff are reminded to check temperatures daily and ensure that thermometers 
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are working correctly as required for proper storage of investigational products (Bednar et al., 
2015). 
 
9.5  Concomitant Medication(s) 
All allowed medication should be maintained at a stable dose from the day of the screening 
and through completion of study treatment. Any change should be carefully reviewed by the 
investigator and the study Medical Monitor for any potential to impact subject safety or the study 
efficacy endpoints. 
            All concomitant medications taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration and all subjects are supposed to be questioned 
about concomitant medication at each clinic visit. 
            Note: A Prohibited/Allowed Concomitant Medication guidance document has been issued 
to each site in addition to the specifications below. 
 
The following drugs and classes of drugs are prohibited as concomitant medications after 
the Screening Visit (Bednar et al., 2015): 
 
 amphotericin B 
 cyclosporine 
 digoxin, digitalis 
 St. John's wort 
 Systemic steroids (topical steroids allowed) 
 antifungal medication such as itraconazole, ketoconazole, posaconazole, voriconazole 
 birth control pills and other hormones 
 Salicylate, aspirin dosing >925 mg/day, warfarin, coumadin 
 Diuretics, furosemide 
 the hepatitis C medications boceprevir or telaprevir 
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 HIV or AIDS medicine such as atazanavir, delavirdine, efavirenz, fosamprenavir, indinavir, 
nelfinavir, nevirapine, ritonavir, saquinavir; 
 insulin or diabetes medications per mouth 
 a Non-Steroidal Anti-Inflammatory Drug (NSAID) such as aspirin, ibuprofen (Advil, Motrin), 
naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others 
 seizure medications such as carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, 
primidone 
 the tuberculosis medications isoniazid, rifabutin, rifapentine, or rifampin 
 chemotherapeutic drugs only (e.g., cis-platinum, carboplatin, present or previous use) 
 Any other drug or supplement that presents risk for impact on hearing or the study efficacy 
assessments e.g. Fish Oil -omega-3 polyunsaturated fatty acids, Vitamin B12-cyanocobalamin,  
Vitamin D3-cholecalciferol 
 Medication interacting with prednisone such as Advair Diskus (fluticasone / salmeterol), Cymbalta 
(duloxetine), Lipitor (atorvastatin), Lyrica (pregabalin), Nexium (esomeprazole), Plaquenil 
(hydroxychloroquine), Prilosec (omeprazole), ProAir HFA (albuterol), Singulair (montelukast), 
Spiriva (tiotropium), Symbicort (budesonide / formoterol), Synthroid (levothyroxine), Tylenol 
(acetaminophen), Xanax (alprazolam), Zyrtec (cetirizine) 
 Medication interacting with magnesium aspartate such as Tivicay (dolutegravir), Triumeq (abacavir 
/ dolutegravir / lamivudine), abacavir / dolutegravir / lamivudine, dolutegravir. 
Medications taken within 28 days before the first dose of study medication will be 
documented as a prior medication. Medications taken after the first dose of study medication will 
be documented as concomitant medications (https://www.drugs.com/drug-
interactions/prednisone.html; https://www.drugs.com/drug-interactions/magnesium-aspartate-
index.html?filter=3&generic_only=). 
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  CHAPTER 10  
STATISTICAL CONSIDERATIONS   
 
 
 
 
10.1  Sample size determination 
Depending on the type of study design and the studies outcome, there are several different 
formulas for the sample size calculation. When an RCT is about to be performed, it is a matter of 
great importance to include enough patients in the study arms of the trial, in order to find as 
statistically significant a difference that we assume there is in the population (Noordzij et al., 
2010). 
In practice, there are several complicating factors regarding the sample size determination 
presenting severe practical difficulties.  
The first complication is that the formula is only approximate and based on the assumption 
that the test of significance will be carried out using a known standard deviation. The problem is 
that we do not know what the sample standard deviation will be until we have run the trial but we 
need to plan the trial before we can run it. Thus we have to make some sort of guess as to what the 
true standard deviation is for the purpose of planning, even if for the purpose of analysis this guess 
is not needed. 
Secondly, a further source of uncertainty into sample size calculation is introduced which 
is not usually taken into account in any formulae commonly employed.  
In practice the statistician tries to obtain a reasonable estimate of the likely standard 
deviation by looking at previous trials.  
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The third complication is that there is usually no agreed standard for a clinically relevant 
difference. In practice some compromise is usually reached between ‘true’ clinical requirements 
and practical sample size requirements.  
Fourth, the levels of significance and of statistical power of the statistical test are 
themselves arbitrary. Frequently, the values chosen in our example (α=0.05 and 1-β=0.80 or 80%) 
are the ones employed. The level of significance α is the probability of a type I error, given that 
the null hypothesis is true, while β is the probability of a type II error, given that the alternative 
hypothesis is true. 
The problem that this raises is frequently ignored. However, where this requirement 
applies, unless the sample size is increased to take account of it, the power will be reduced (Senn, 
2008). 
Regarding our study, the simple formula below is adequate for giving a basic impression 
of the calculations required to establish a sample size: 
 
2 2
2
4 ( )crit Zpwr
n
   

  
Where: 
n is the total sample size (the sum of the sizes of both comparison groups),  
σ is the assumed SD of each group (assumed to be equal for both groups),  
Ζcrit is the value of the Normal distribution which cuts off an upper tail probability of a/2, for a 
desired level of significance α,  
Ζpwr is the value of the Normal distribution which cuts off an upper tail probability of β, for a 
desired statistical power 1-β, and  
Δ is the minimum expected difference between the two means. 
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On the basis of preliminary results from the previous phases of this study, as investigators, 
we estimate that the magnesium prednisone combination treatment will help the study subjects 
have an improvement of PTA results by 20 dB, whereas prednisone alone only by 10 dB.  
The above equation will be used to determine the sample size for a study with the 
magnesium and placebo both combined with prednisone, with an expected mean difference of 10 
dB and an expected standard deviation of 27.31 dB (Bogaz et al., 2014; Röhrig et al., 2010).  
The two-tailed unpaired t-test is to be used, with the level of significance of α=5% and the 
power of 80%. According to statistical Tables of Normal distribution, Z0.8 = 0.8416 and Z0.975 = 
1.96. If these values are inserted into the above equation, they give the total sample size as follows 
(Senn, 2008): 
 
 
2 2 2 2
0.975 0.8
2 2
4 ( ) 4 (1.96 0.8416) 27.31
234
10
Z
n
      
  

 
 
Both Zcrit and Zpwr are cutoff points along the x axis of a standard normal probability 
distribution that demarcate probabilities matching the specified significance level and statistical 
power, respectively. The two groups that make up n are assumed to be equal in number, and it is 
assumed that two-tailed statistical analysis will be used (Eng, 2003). 
Assuming a 15% drop-out rate of the initial number of subjects enrolled to this trial, a total 
number of n=270 subjects will have to be randomized. 
 
10.2  Efficacy Analysis 
Primary Efficacy Analysis 
All subjects that complete at least the first treatment dose will be included in the efficacy 
data analyses as appropriate. The primary endpoint for this study is the change from baseline to 
Tmax in Pure Tone Audiometry (PTA), averaged over 2 kHz and 4 kHz frequencies measured in 
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the worst ear. Descriptive statistics (arithmetic mean, sample standard deviation, median, 
minimum and maximum) will be computed and tabulated by treatment. 
Significant difference with regards to the primary endpoint mean change between the study 
groups will be determined using two-sample independent t-test (2-sided) at 5% level of 
significance (Bednar et al., 2015). 
 
Analysis of Secondary Efficacy Endpoints 
The secondary efficacy endpoints are: 
o Change from baseline in PTA, averaged over 2 kHz and 4 kHz frequencies. 
o Change from baseline in SDS measured in the worst hearing ear as defined by PTA at 
baseline. 
o Change from baseline in SINT. 
o Change from baseline in Tinnitus Severity Ranking Scale. 
 
The analysis of the secondary endpoints of change from baseline in PTA, SDS, SINT, 
Tinnitus Severity Ranking Scale will be conducted using the Hotelling’s T square test for two 
independent samples. 
The Speech Discrimination Score (SDS) will be analyzed using the total number of 
phonemes correctly repeated back by the subject.  
Subsequently the mean change from baseline values will be compared between each of the 
two study groups. 
Descriptive statistics (arithmetic mean, sample standard deviation, median, minimum and 
maximum) will be computed and tabulated by treatment for all secondary endpoints (Bednar et al., 
2015). 
 
10.3 Safety Analysis  
The Safety Analysis population consists of all randomized subjects who receive at least 
one dose of randomized study drug. The term “on treatment” refers to the period between the first 
administration of study drug and two days after the last administration of study drug. This period 
will be the basis for the safety analysis.  
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Safety and tolerability will be evaluated taking into consideration the patients’ vital signs 
(supine and standing BP and pulse rate), ECG and clinical laboratory changes from baseline will 
be assessed for clinically relevant change. 
Adverse events, ECG, blood pressure (supine and standing), pulse rate, and safety 
laboratory data will be reviewed on a regular basis during the study to evaluate the safety of 
subjects. Any laboratory, ECG and BP abnormalities of potential clinical concern will be 
described. Safety data will be presented in tabular and/or graphical format and summarized 
descriptively, where appropriate. 
In case of any untoward findings identified on physical and/or neurologic exams conducted 
after the administration of the first dose of study medication, those findings meet the definition of 
an adverse event.  
Effects of treatment will be evaluated using descriptive statistics (mean, standard deviation, 
median, minimum and maximum) for baseline, post-baseline and change from baseline values for 
each treatment. Statistical inference might be made for certain adverse events of medical interest. 
 
Primary Safety Analysis  
The principal safety end points is a composite of major and no major clinically relevant 
adverse events. The principal safety objective of this study is to demonstrate that the combination 
therapy of magnesium with corticosteroids is superior to corticosteroids alone.  
 
 
10.4 Interim Analysis  
An interim analysis will be performed, when either 50% of the primary efficacy endpoint 
events, as reported by the Clinical Endpoint Committee (CEC), have occurred, or at a maximum 
of 36 months after the first subject is randomized. The purpose of this interim analysis is to stop 
the study early if it is unlikely to establish non-inferiority for the primary efficacy endpoint, if the 
study were to run to completion. In other words the objective of the interim analysis is to stop the 
study early due to lack of efficacy. The study will NOT be terminated early to declare non-
inferiority. 
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